Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.
Michael A. Savin, MD
Advertisement
Articles by Michael A. Savin, MD
Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.
Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the future of biosimilars in oncology.
Advertisement
Latest Updated Articles
Dr. Savin Discusses the Future of Biosimilars in OncologyPublished: June 12th 2018 | Updated:
Dr. Savin on the Evolution of BiosimilarsPublished: June 16th 2018 | Updated:
Dr. Savin on the Challenges of Developing Biosimilar Clinical TrialsPublished: August 17th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5